CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy

Urol Int. 2012;88(2):158-64. doi: 10.1159/000335299. Epub 2012 Jan 28.

Abstract

Introduction: The cell surface endopeptidase CD10 (neutral endopeptidase) and nuclear factor-κB (NF-κB) have been independently associated with prostate cancer (PC) progression. We investigated the correlations between these two factors and their prognostic relevance in terms of biochemical (prostate-specific antigen, PSA) relapse after radical prostatectomy (RP) for localized PC.

Patients and methods: The immunohistochemical expression of CD10 and NF-κB in samples from 70 patients who underwent RP for localized PC was correlated with the preoperative PSA level, Gleason score, pathological stage and time to PSA failure.

Results: CD10 expression was inversely associated with NF-κB expression (p < 0.001), stage (p = 0.03) and grade (p = 0.003), whereas NF-κB was directly related with stage (p = 0.006) and grade (p = 0.002). The median time to PSA failure was 56 months. CD10 and NF-κB were directly (p < 0.001) and inversely (p < 0.001) correlated with biochemical recurrence-free survival, respectively. CD10 expression (p = 0.022) and stage (p = 0.018) were independently associated with time to biochemical recurrence.

Conclusion: Low CD10 expression is an adverse prognostic factor for biochemical relapse after RP in localized PC, which is also associated with high NF-κB expression. Decreased CD10 expression which would lead to increased neuropeptide signaling and NF-κB activity may be present in a subset of early PCs.

MeSH terms

  • Aged
  • Chi-Square Distribution
  • Disease Progression
  • Disease-Free Survival
  • Down-Regulation
  • Greece
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Multivariate Analysis
  • NF-kappa B / analysis*
  • Neoplasm Grading
  • Neoplasm Recurrence, Local*
  • Neoplasm Staging
  • Neprilysin / analysis*
  • Proportional Hazards Models
  • Prostate-Specific Antigen / blood*
  • Prostatectomy / adverse effects*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / chemistry*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Failure
  • Up-Regulation

Substances

  • NF-kappa B
  • Prostate-Specific Antigen
  • Neprilysin